Leflunomide Elvim (Leflunomide)

Leflunomide works by inhibiting dihydroorotate dehydrogenase, an enzyme required for de novo pyrimidine synthesis. This limits the production of nucleotides needed for rapidly dividing immune cells, especially activated T‑lymphocytes, thereby dampening the autoimmune response that drives arthritis.

The dosing regimen for leflunomide is individualized by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other medications. The prescriber determines the appropriate loading and maintenance doses and provides specific instructions.

Leflunomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated during pregnancy and women of child‑bearing potential must use effective contraception. Breastfeeding is also not recommended while taking leflunomide.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Leflunomide Elvim. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leflunomide is often compared with methotrexate, another first‑line DMARD. Both suppress immune activity, but leflunomide primarily inhibits pyrimidine synthesis while methotrexate interferes with folate metabolism. Their safety profiles differ; leflunomide has a higher risk of liver enzyme elevation, whereas methotrexate is more associated with mucosal ulcers and pulmonary toxicity.

Leflunomide Elvim tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Leflunomide Elvim is taken orally as a tablet with or without food, according to the prescriber’s instructions. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically advised by a healthcare professional.

Serious risks include severe liver injury, bone‑marrow suppression leading to anemia or low white‑blood‑cell counts, and interstitial lung disease. Patients should be monitored regularly for liver function, complete blood counts and respiratory symptoms, and any signs of infection or unusual bleeding should prompt immediate medical evaluation.

Leflunomide is contraindicated in pregnant women, individuals with severe hepatic impairment, active infections, or known hypersensitivity to leflunomide. Patients with uncontrolled hypertension or a history of severe lung disease should also avoid the drug unless a specialist determines that benefits outweigh the risks.